Cetuximab and Trastuzumab in Treating Patients With Metastatic Pancreatic Cancer That Progressed After Previous Treatment With Gemcitabine

DISEASE CHARACTERISTICS: * Histologically confirmed metastatic adenocarcinoma of the pancreas * Progressed after first-line or adjuvant gemcitabine-based chemotherapy * Measurable disease as assessed by RECIST criteria * No known brain metastasis or symptomatic carcinomatous leptomeningitis PATIENT CHARACTERISTICS: * WHO performance status 0-1 * Life expectancy ≥ 3 months * ANC ≥ 1,500/mm\^3 * Platelet count ≥ 100,000/mm\^3 * Hemoglobin ≥ 9 g/dL * Creatinine ≤ 1.5 times upper limit of normal (ULN) * Total bilirubin ≤ 2.5 times ULN * ALT/AST ≤ 5 times ULN * LVEF ≥ 55% * Not pregnant or nursing * Fertile patients must use effective contraception * No significant comorbidities, including any of the following: * Cardiovascular disease * Documented history of congestive heart failure * Uncontrolled, high-risk arrhythmia * Angina pectoris requiring treatment * Clinically significant valvular disease * Evidence of transmural myocardial infarction by ECG * Uncontrolled hypertension * Active bleeding * Clinically significant active infection * Severe dyspnea at rest * Oxygen-dependency * No other malignancy except basal cell carcinoma of the skin * No severe hypersensitivity to cetuximab or trastuzumab * No medical or psychological condition that would preclude study completion or giving informed consent * No legal incapacity or limited legal capacity PRIOR CONCURRENT THERAPY: * See Disease Characteristics * No prior cetuximab or trastuzumab * No other concurrent experimental drugs or anticancer therapy